PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29674626-3	2018	We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).	Prednisone	196-206	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	97-100	
30501868-2	2018	Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment.	Prednisone	105-115	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	177-180	
25468432-3	2015	Molecular analyses support the concept that there is a biological continuum between BL and DLBCL that includes variable activity of MYC, an oncoprotein once thought to be only associated with BL, but now recognized as a major predictor of survival among patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).	Prednisone	354-364	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	132-135	
28291124-2	2017	MYC, a transcriptional factor and oncoprotein, is overexpressed in a fraction of DLBCL and indicates poor prognosis and aggressive clinical course when treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).	Prednisone	228-238	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3	
24719189-1	2014	This study aims to investigate the prognostic significance of the MYC protein expression in diffuse large B cell lymphoma (DLBCL) patients treated with RCHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone).	Prednisone	222-232	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	66-69	
25073258-5	2013	Our patient showed a high dermal Ki-67 level and concomitant C-MYC/8q24 translocation, which may account for the aggressive clinical course and refractoriness to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.	Prednisone	216-226	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	61-66	
22851565-0	2012	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Prednisone	147-157	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	25-28	
23335369-1	2013	MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP) and rituximab (R)-CHOP treated patients.	Prednisone	164-174	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-3	
20498406-2	2010	The aim of this study was to determine the frequency of MYC translocations in DLBCL and their prognostic impact in the era of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (CHOP-R) therapy.	Prednisone	174-184	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	56-59	
22213394-2	2012	The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.	Prednisone	166-176	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	96-99	
34732441-6	2021	Moreover, high risk, defined as co-expression of BTK and either or both BCL2/MYC, independently predicted shorter progression-free survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) (all R-CHOP-treated patients: hazard ratio=2.565, p=0.044; R-CHOP-treated non-GCB subgroup: HR=3.833, p=0.019).	Prednisone	227-237	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	77-80